Health Affairs November 1, 2023
Earlier this summer, the Centers for Medicare and Medicaid Services (CMS) received an important signal from the health policy community: Just as patient-centricity has become an expectation for research, stakeholders expect CMS to adopt a patient-centered approach in implementing its historic drug price negotiation authority under the Inflation Reduction Act. In response, CMS has committed to holding “patient-focused listening sessions” to help determine the “maximum fair price” for drugs under the Drug Price Negotiation Program. According to the agency, these meetings will be open to the public, including “patients, beneficiaries, caregivers, consumer and patient advocacy organizations, health care providers, and other interested parties to share patient-focused input on therapeutic alternative(s) and other data on the factors in section 1194(e)(2) [of...
Today's Sponsors
Today's Sponsor